X

Trial Profile

Phase 1 study to analyze the safety and tolerability of NN3201

Status: Not yet recruiting

Phase of Trial: Phase I

Latest Information Update: 25 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NN 3201 (Primary)
Indications Adenocarcinoma; Gastric cancer; Gastrointestinal stromal tumours; Neuroendocrine tumours; Small cell lung cancer; Solid tumours
Focus Adverse reactions

Most Recent Events

25 Dec 2024 New trial record
19 Dec 2024 According to NoveltyNobility media release, This phase 1 clinical trial will be conducted in the United States from the second half of this year.
11 Nov 2024 According to a NoveltyNobility media release, the company received approval for a phase 1 clinical trial plan (IND) from the U.S. Food and Drug Administration (FDA) in May and aims to administer the first patient in the first half of next year.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com